LAG525
Total Payments
$2.0M
Transactions
51
Doctors
6
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $140,973 | 8 | 0 |
| 2019 | $326,700 | 12 | 0 |
| 2018 | $880,943 | 21 | 6 |
| 2017 | $651,567 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.0M | 51 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF LAG525 SINGLE AGENT AND IN COMBINATION WITH PDR001 ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $1.8M | 0 |
| A PHASE II OPEN LABEL RANDOMIZED THREE ARM MULTICENTER STUDY OF LAG525 GIVEN IN COMBINATION WITH SPARTALIZUMAB PDR001 OR WITH SPARTALIZUMAB AND CARBOPLATIN OR WITH CARBOPLATIN AS FIRST OR SECOND LINE THERAPY IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAS | Novartis Pharmaceuticals Corporation | $144,323 | 0 |
| A PHASE II OPEN LABEL RANDOMIZED THREE ARM MULTICENTER STUDY OF LAG525 GIVEN IN COMBINATION WITH SPARTALIZUMAB PDR001 OR WITH SPARTALIZUMAB AND CARBOPLATIN OR WITH CARBOPLATIN AS FIRST OR SECOND LINE THERAPY IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER | Novartis Pharmaceuticals Corporation | $10,202 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,341 | 4 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $687.60 | 6 |
Top Doctors Receiving Payments for LAG525
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $2.0M | 41 |
| , M.D | Medical Oncology | New York, NY | $449.75 | 2 |
| , M.D | Medical Oncology | Durham, NC | $449.75 | 2 |
| , MD | Medical Oncology | Salt Lake City, UT | $449.75 | 2 |
| , M.D | Hematology & Oncology | New York, NY | $449.75 | 2 |
| , M.D | Medical Oncology | Houston, TX | $114.60 | 1 |
| , M.D | Medical Oncology | San Antonio, TX | $114.60 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.0M
- Total Doctors 6
- Transactions 51
About LAG525
LAG525 is a drug associated with $2.0M in payments to 6 healthcare providers, recorded across 51 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $140,973 was paid across 8 transactions to 0 doctors.
The most common payment nature for LAG525 is "Unspecified" ($2.0M, 100.0% of total).
LAG525 is associated with 5 research studies, including "A PHASE I AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF LAG525 SINGLE AGENT AND IN COMBINATION WITH PDR001 ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANCIES" ($1.8M).